Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBIO BridgeBio Pharma	$33.71 +0.1%	$34.48	$21.62 ▼ $39.54	$6.40B	1.15	2.43 million shs	2.23 million shs
INDV Indivior	$11.44 -2.1%	$10.18	$7.33 ▼ $18.59	$1.61B	0.98	1.01 million shs	568,314 shs
TLX Telix Pharmaceuticals Limited American Depositary Shares	$16.40 -0.8%	$16.96	$13.61 ▼ $30.36	$5.54B	N/A	26,748 shs	12,603 shs
VRNA Verona Pharma	$74.73 +3.0%	$63.96	$11.39 ▼ $75.47	$6.06B	0.2	1.29 million shs	1.61 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBIO BridgeBio Pharma	+0.06%	+1.35%	-0.47%	-7.11%	+14.19%
INDV Indivior	-2.05%	+2.23%	+26.97%	+4.88%	-33.06%
TLX Telix Pharmaceuticals Limited American Depositary Shares	-0.85%	-1.86%	-1.86%	-4.60%	+1,639,999,900.00%
VRNA Verona Pharma	+2.96%	+10.60%	+26.83%	+16.80%	+484.74%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BBIO BridgeBio Pharma	4.6499 of 5 stars	4.5	2.0	0.0	3.9	3.3	3.3	0.6
INDV Indivior	3.3386 of 5 stars	3.6	3.0	0.0	0.0	2.6	1.7	1.9
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VRNA Verona Pharma	1.885 of 5 stars	2.6	1.0	0.0	0.0	4.2	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBIO BridgeBio Pharma	2.92	Moderate Buy	$57.09	69.36% Upside
INDV Indivior	3.25	Buy	$15.00	31.12% Upside
TLX Telix Pharmaceuticals Limited American Depositary Shares	3.00	Buy	$22.00	34.15% Upside
VRNA Verona Pharma	3.11	Buy	$81.50	9.06% Upside

Current Analyst Ratings Breakdown

Latest INDV, BBIO, VRNA, and TLX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/30/2025	BBIO BridgeBio Pharma	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$46.00 ➝ $63.00
4/30/2025	BBIO BridgeBio Pharma	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$52.00 ➝ $55.00
4/30/2025	BBIO BridgeBio Pharma	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$65.00 ➝ $72.00
4/30/2025	VRNA Verona Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$93.00 ➝ $107.00
4/30/2025	VRNA Verona Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$75.00 ➝ $85.00
4/28/2025	VRNA Verona Pharma	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
4/28/2025	VRNA Verona Pharma	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$100.00
4/21/2025	VRNA Verona Pharma	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$80.00
4/15/2025	BBIO BridgeBio Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$49.00 ➝ $53.00
3/31/2025	BBIO BridgeBio Pharma	Redburn Atlantic Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$50.00
3/24/2025	BBIO BridgeBio Pharma	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$44.00 ➝ $50.00

(Data available from 5/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBIO BridgeBio Pharma	$127.42M	50.24	N/A	N/A	($7.71) per share	-4.37
INDV Indivior	$1.17B	1.35	$2.32 per share	4.94	N/A	∞
TLX Telix Pharmaceuticals Limited American Depositary Shares	$783.21M	7.08	N/A	N/A	N/A	∞
VRNA Verona Pharma	$118.54M	51.12	N/A	N/A	$3.10 per share	24.11

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBIO BridgeBio Pharma	-$535.76M	-$3.53	N/A	N/A	N/A	-241.44%	N/A	-75.69%	8/7/2025 (Estimated)
INDV Indivior	$2M	-$0.31	N/A	6.69	N/A	-3.96%	-241.73%	15.09%	7/24/2025 (Estimated)
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A	N/A	0.00	34.17	N/A	N/A	N/A	N/A	N/A
VRNA Verona Pharma	-$54.37M	-$2.00	N/A	2,491.00	N/A	N/A	-79.54%	-43.49%	N/A

Latest INDV, BBIO, VRNA, and TLX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
4/29/2025	Q1 2025	BBIO BridgeBio Pharma	-$1.00	-$0.88	+$0.12	-$0.88	$57.14 million	$36.74 million
4/29/2025	Q1 2025	VRNA Verona Pharma	-$0.22	$0.27	+$0.49	-$0.16	$41.47 million	$98.65 million
4/24/2025	Q1 2025	INDV Indivior	$0.22	$0.41	+$0.19	$0.38	$240.13 million	$266.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
INDV Indivior	N/A	N/A	N/A	N/A	N/A
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A	N/A	N/A	N/A	N/A
VRNA Verona Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBIO BridgeBio Pharma	N/A	4.67	4.67
INDV Indivior	N/A	0.83	0.65
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A	N/A	N/A
VRNA Verona Pharma	0.93	13.03	12.88

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBIO BridgeBio Pharma	99.85%
INDV Indivior	60.33%
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A
VRNA Verona Pharma	85.88%

Insider Ownership

Company	Insider Ownership
BBIO BridgeBio Pharma	18.20%
INDV Indivior	N/A
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A
VRNA Verona Pharma	4.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBIO BridgeBio Pharma	400	189.88 million	143.29 million	Optionable
INDV Indivior	1,164	137.88 million	N/A	Not Optionable
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A	337.88 million	N/A	N/A
VRNA Verona Pharma	30	81.08 million	76.10 million	Optionable

INDV, BBIO, VRNA, and TLX Headlines

Recent News About These Companies

Verona Pharma Announces June 2025 Investor Conference Participation

May 21 at 6:00 AM | globenewswire.com

Verona Pharma plc (NASDAQ:VRNA) Shares Bought by Lazard Asset Management LLC

May 21 at 4:34 AM | marketbeat.com

Point72 Asset Management L.P. Buys New Position in Verona Pharma plc (NASDAQ:VRNA)

May 19 at 5:53 AM | marketbeat.com

1,821,019 Shares in Verona Pharma plc (NASDAQ:VRNA) Acquired by RTW Investments LP

May 18 at 6:54 AM | marketbeat.com

39,369 Shares in Verona Pharma plc (NASDAQ:VRNA) Acquired by Point72 Europe London LLP

May 18 at 6:15 AM | marketbeat.com

Verona Pharma plc (NASDAQ:VRNA) Receives Consensus Rating of "Buy" from Analysts

May 18 at 1:57 AM | marketbeat.com

Verona Pharma plc (NASDAQ:VRNA) Stake Lifted by Parkman Healthcare Partners LLC

May 16, 2025 | marketbeat.com

Nicholas Investment Partners LP Invests $7.19 Million in Verona Pharma plc (NASDAQ:VRNA)

May 16, 2025 | marketbeat.com

Nuance Pharma Announces Ensifentrine Meets Primary Endpoint in Phase 3 ENHANCE-CHINA Trial for COPD

May 16, 2025 | taiwannews.com.tw

Verona Pharma plc (NASDAQ:VRNA) Receives Average Rating of "Buy" from Brokerages

May 16, 2025 | americanbankingnews.com

Octagon Capital Advisors LP Sells 1,263,936 Shares of Verona Pharma plc (NASDAQ:VRNA)

May 15, 2025 | marketbeat.com

Verona Pharma plc (NASDAQ:VRNA) Shares Bought by Janus Henderson Group PLC

May 15, 2025 | marketbeat.com

Raymond James Financial Inc. Invests $225,000 in Verona Pharma plc (NASDAQ:VRNA)

May 15, 2025 | marketbeat.com

Why Verona Pharma plc (VRNA) is Among the Best Performing Healthcare Stocks to Buy Now

May 13, 2025 | insidermonkey.com

Fred Alger Management LLC Takes $1.34 Million Position in Verona Pharma plc (NASDAQ:VRNA)

May 13, 2025 | marketbeat.com

Verona Pharma plc (NASDAQ:VRNA) Shares Acquired by Barclays PLC

May 13, 2025 | marketbeat.com

Findell Capital Management LLC Makes New $8.36 Million Investment in Verona Pharma plc (NASDAQ:VRNA)

May 11, 2025 | marketbeat.com

The Manufacturers Life Insurance Company Has $5.89 Million Stock Position in Verona Pharma plc (NASDAQ:VRNA)

May 10, 2025 | marketbeat.com

Deep Track Capital LP Sells 2,330,025 Shares of Verona Pharma plc (NASDAQ:VRNA)

May 9, 2025 | marketbeat.com

Duquesne Family Office LLC Purchases 201,535 Shares of Verona Pharma plc (NASDAQ:VRNA)

May 9, 2025 | marketbeat.com

Verona Pharma plc (NASDAQ:VRNA) Insider Sells $1,014,158.88 in Stock

May 9, 2025 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

INDV, BBIO, VRNA, and TLX Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

$33.71 +0.02 (+0.06%)

As of 05/20/2025 04:00 PM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Indivior NASDAQ:INDV

$11.44 -0.24 (-2.05%)

As of 05/20/2025 04:00 PM Eastern

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Telix Pharmaceuticals Limited American Depositary Shares NASDAQ:TLX

$16.40 -0.14 (-0.85%)

As of 05/20/2025 03:59 PM Eastern

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

Verona Pharma NASDAQ:VRNA

$74.73 +2.15 (+2.96%)

As of 05/20/2025 04:00 PM Eastern

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time